{"id":"https://openalex.org/W2117970531","doi":"https://doi.org/10.1128/aac.01753-09","title":"Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions","display_name":"Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-11","ids":{"openalex":"https://openalex.org/W2117970531","doi":"https://doi.org/10.1128/aac.01753-09","mag":"2117970531","pmid":"https://pubmed.ncbi.nlm.nih.gov/20457817","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2916350"},"language":"en","primary_location":{"id":"doi:10.1128/aac.01753-09","doi":"https://doi.org/10.1128/aac.01753-09","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.01753-09","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2117970531"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2916350/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108538446","display_name":"Yigong Ge","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yigong Ge","raw_affiliation_strings":["Calixa Therapeutics, Inc., San Diego, California","Calixa Therapeutics, Inc., San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Calixa Therapeutics, Inc., San Diego, California","institution_ids":[]},{"raw_affiliation_string":"Calixa Therapeutics, Inc., San Diego, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021508578","display_name":"M.J. Whitehouse","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. J. Whitehouse","raw_affiliation_strings":["JumpStart BioDevelopment, San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"JumpStart BioDevelopment, San Francisco, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112130576","display_name":"Ian R. Friedland","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ian Friedland","raw_affiliation_strings":["Calixa Therapeutics, Inc., San Diego, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Calixa Therapeutics, Inc., San Diego, California","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080609948","display_name":"George H. Talbot","orcid":"https://orcid.org/0000-0002-2868-2707","observed_orcids":["https://orcid.org/0000-0002-2868-2707"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"George H. Talbot","raw_affiliation_strings":["Talbot Advisors LLC, Wayne, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Talbot Advisors LLC, Wayne, Pennsylvania","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.376,"has_fulltext":false,"cited_by_count":54,"citation_normalized_percentile":{"value":0.91017917,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"54","issue":"8","first_page":"3427","last_page":"3431"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9850000143051147},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8640000224113464},{"id":"https://openalex.org/keywords/single-dose-administration","display_name":"single-dose administration","score":0.722000002861023},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.9779999852180481},{"id":"https://openalex.org/keywords/dose-linearity","display_name":"dose linearity","score":0.656000018119812},{"id":"https://openalex.org/keywords/plasma-half-life","display_name":"plasma half-life","score":0.8379999995231628},{"id":"https://openalex.org/keywords/renal-excretion","display_name":"renal excretion","score":0.9580000042915344},{"id":"https://openalex.org/keywords/infusion-site-reactions","display_name":"infusion site reactions","score":0.6069999933242798},{"id":"https://openalex.org/keywords/serious-bacterial-infection","display_name":"serious bacterial infection","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8441189527511597},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7716304659843445},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7618551254272461},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7338389158248901},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5568559169769287},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4828565716743469},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.47109541296958923},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.450709730386734},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4186994731426239},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3657674789428711},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1128/aac.01753-09","doi":"https://doi.org/10.1128/aac.01753-09","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.01753-09","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2916350","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2916350/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:20457817","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20457817","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.862.2135","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.862.2135","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://aac.asm.org/content/54/8/3427.full.pdf","raw_type":"text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2916350","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2916350/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W1966831828","https://openalex.org/W1984024012","https://openalex.org/W2025878629","https://openalex.org/W2074669461","https://openalex.org/W2103382313","https://openalex.org/W2115486016","https://openalex.org/W2119629693","https://openalex.org/W2135088547","https://openalex.org/W2137755807","https://openalex.org/W2155116575","https://openalex.org/W2156522255","https://openalex.org/W2168519960","https://openalex.org/W2331850175"],"related_works":["https://openalex.org/W4237410394","https://openalex.org/W2035619832","https://openalex.org/W2059958957","https://openalex.org/W2108985755","https://openalex.org/W2782246563","https://openalex.org/W2016815689","https://openalex.org/W2070281742","https://openalex.org/W2050259485"],"abstract_inverted_index":{"CXA-101":[0,24,54,169,196,235],"is":[1],"a":[2,58,120,199],"novel,":[3],"broad-spectrum":[4],"cephalosporin":[5],"with":[6],"excellent":[7],"antipseudomonal":[8],"activity.":[9],"A":[10],"Phase":[11],"1":[12,32,42,76],"study":[13],"was":[14,167,177,188,202],"performed":[15],"to":[16,34,212,220],"determine":[17],"the":[18,44,138,173,185,242],"safety,":[19],"tolerability,":[20],"and":[21,27,37,55,69,77,82,89,107,113,124,146,205,215,230],"pharmacokinetics":[22],"of":[23,43,48,64,184,234,244],"after":[25],"single-":[26],"multiple-dose":[28,155],"intravenous":[29],"administration":[30],"over":[31,224],"h":[33],"healthy":[35],"male":[36],"female":[38],"subjects.":[39],"In":[40,72,194],"part":[41,73],"study,":[45],"five":[46],"cohorts":[47,75],"eight":[49],"subjects":[50,132],"each":[51,98],"(six":[52],"receiving":[53,57],"two":[56],"placebo)":[59],"received":[60,79,92,100],"single":[61,209],"ascending":[62],"doses":[63,210,218],"250,":[65],"500,":[66],"1,000,":[67],"1,500,":[68],"2,000":[70,213],"mg.":[71],"2,":[74],"2":[78],"500":[80],"mg":[81,94,214],"1,000":[83],"mg,":[84],"respectively,":[85],"every":[86,95],"8":[87],"h,":[88],"cohort":[90,99],"3":[91,221],"1,500":[93],"12":[96],"h;":[97],"dosing":[101],"for":[102,241],"10":[103,225],"days.":[104,226],"Standard":[105],"safety":[106,229],"tolerability":[108],"assessments":[109],"were":[110,117,144],"performed.":[111],"Blood":[112],"urine":[114],"pharmacokinetic":[115,232],"samples":[116],"assayed":[118],"by":[119],"validated":[121],"bioanalytical":[122],"method":[123],"analyzed":[125],"using":[126],"standard":[127],"noncompartmental":[128],"methodology.":[129],"All":[130],"64":[131],"completed":[133],"dosing;":[134],"none":[135],"withdrew":[136],"from":[137],"study.":[139],"Drug-related":[140],"systemic":[141],"adverse":[142],"events":[143,152],"infrequent":[145],"mild.":[147],"Mild,":[148],"non-treatment-limiting":[149],"infusion":[150,201],"site":[151],"occurred":[153],"during":[154],"administration.":[156],"No":[157],"clinically":[158],"significant":[159],"laboratory":[160],"or":[161,164],"electrocardiographic":[162],"finding":[163],"dose-limiting":[165],"toxicity":[166],"observed.":[168],"exhibited":[170],"dose-linear":[171],"pharmacokinetics;":[172],"mean":[174],"plasma":[175],"half-life":[176],"approximately":[178],"2.3":[179],"h.":[180],"More":[181],"than":[182],"90%":[183],"administered":[186,197],"dose":[187],"eliminated":[189],"unchanged":[190],"through":[191],"renal":[192],"excretion.":[193],"summary,":[195],"as":[198],"1-hour":[200],"generally":[203],"safe":[204],"well":[206],"tolerated":[207],"in":[208,216],"up":[211,219],"multiple":[217],"g":[222],"daily":[223],"The":[227],"favorable":[228],"predictable":[231],"profile":[233],"support":[236],"its":[237],"continuing":[238],"clinical":[239],"development":[240],"treatment":[243],"serious":[245],"bacterial":[246],"infections.":[247]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2117970531","counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
